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Abstract 
Introduction 
The Electronic Health Records for Clinical Research (EHR4CR) technological platform 
has been developed to enable the trustworthy reuse of hospital electronic health records 
data for clinical research. The EHR4CR platform can enhance and speed up clinical 
research scenarios:  protocol feasibility assessment, patient identification for recruitment 
in clinical trials, and clinical data exchange, including for reporting serious adverse 
events. Our objective was to seed a multi-stakeholder ecosystem to enable the scalable 
exploitation of the EHR4CR platform in Europe, and to assess its economic 
sustainability. 
Materials and methods 
Market analyses were conducted by a multidisciplinary task force to define an EHR4CR 
emerging ecosystem and multi-stakeholder value chain. This involved mapping 
stakeholder groups and defining their unmet needs, incentives, potential barriers for 
adopting innovative solutions, roles and interdependencies. A comprehensive business 
model, value propositions, and sustainability strategies were developed accordingly. 
Using simulation modelling (including Monte Carlo simulations) and a 5-year horizon, 
the potential financial outcomes of the business model were forecasted from the 
perspective of an EHR4CR service provider. 
Results 
A business ecosystem was defined to leverage the EHR4CR multi-stakeholder value 
chain. Value propositions were developed describing the expected benefits of EHR4CR 
solutions for all stakeholders. From an EHR4CR service provider’s viewpoint, the 
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business model simulation estimated that a profitability ratio of up to 1.8 could be 
achieved at year 1, with potential for growth in subsequent years depending on projected 
market uptake.  
Conclusions 
By enhancing and speeding up existing processes, EHR4CR solutions promise to 
transform the clinical research landscape. The ecosystem defined provides the 
organisational framework for optimising the value and benefits for all stakeholders 
involved, in a sustainable manner. Our study suggests that the exploitation of EHR4CR 
solutions appears profitable and sustainable in Europe, with a growth potential depending 
on the rates of market and hospital adoption.  
 
Key words:  ecosystem; simulation modelling; business model; value chain; electronic 
health records; clinical research  
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1. Introduction  
The research and development (R&D) of new medicines has become increasingly 
challenging. Studies estimate that it now costs between USD 161 million and 2 billion to 
bring a new drug to market [1]. The main obstacles to conducting clinical trials today 
include high cost, lengthy time frames, administrative barriers and delays in study 
execution [1, 2]. Specific challenges include assessing the feasibility of study protocols, 
targeting the right patient populations, identifying suitable patients for recruitment in 
clinical trials, and enhancing clinical data exchange. These factors explain the interest of 
transforming existing clinical research models so to bring innovative medicines to 
healthcare faster, and at lower cost [2, 3]. 
In addition, achieving success in today’s economy not only demands clever innovation 
and highly performing technology, but agile and incentive-based business models[4]. 
While the term “ business model” is often used, it is seldom defined explicitly[5]. 
Nonetheless, it has evolved considerably in the past decade with the development of 
taxonomies and categorizations [6-13], including the emerging concept of business model 
innovation [14-20]. Nowadays, business models use a system-level approach to define 
the manner and framework within which organisations will create, deliver and capture 
value[20].  In 2009, the “Business Model Canvas” was introduced as a pragmatic 
approach to business modelling [20]. With its nine building blocks, this systematic 
approach also has the merit of synthesizing and providing a general overview of the 
business model, which modular components can be easily updated or reorganised in 
response to a rapidly evolving market. By defining the organisational framework that can 
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optimise full business potential, business models also assist funding and capital 
investment decisions.  
The objective of the Electronic Health Records for Clinical Research (EHR4CR ) 
(http://www.ehr4cr.eu/) was to develop a scalable pan-European platform during a 5-year 
European research project (2011-2015)  funded by the European Commission and by the 
European Federation of Pharmaceutical Industries and Associations (EFPIA), in the 
frame of the Innovative Medicines Initiative Joint Undertaking Programme (IMI-JU)[21]. 
More specifically, this project has developed adaptable, reusable and scalable tools and 
services for reusing data from electronic health records (EHR) systems for clinical 
research purposes. With a budget of over 16 million Euros, the EHR4CR consortium 
involved 34 academic and private partners (10 pharmaceutical companies), and included 
11 hospital sites in France, Germany, Poland, Switzerland and the United Kingdom. It is 
to date one of the largest of the IMI public-private partnership in this area [21].  
Importantly, the EHR4CR platform has been specially designed and engineered to unlock 
the contribution of health data from hospital EHR systems, in compliance with the 
ethical, regulatory and data protection policies and requirements of each participating 
country, to enable three clinical research scenarios (S): Scenario 1 (S1): Improving 
protocol feasibility assessments, Scenario 2 (S2): Enhancing and speeding up patient 
identification for recruitment in clinical trials, and Scenario 3 (S3): Optimising clinical 
trial data exchange, including for the reporting of severe adverse events (SAE) [21]. 
Detailed descriptions of the EHR4CR platform and services have been published [21, 
22]. The EHR4CR platform supports distributed querying to enhance and speed up 
clinical trial feasibility assessments, patient identification for recruitment, and clinical 
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study execution. The platform has been piloted at several large academic hospital sites 
across Europe to demonstrate its functionality, and the effectiveness and security of its 
tools and services. For this purpose, interfaces between the EHR systems and the central 
EHR4CR platform have been established. Semantic mapping between local terminologies 
and the central EHR4CR terminology has been conducted. Clinical data warehouses, 
compliant with the EHR4CR platform and the associated extract–transform–load 
processes have been designed and tested. An inventory of data elements corresponding to 
the most frequently occurring eligibility criteria has been defined.  Approval of all data 
processing steps was gained in accordance with local ethical and legal regulations at each 
site. In particular, as the pilot sites were active in clinical research, they were able to 
provide exemplary local governance requirements to complement the ethical inputs 
referred to above. To enable wide adoption by EHR vendors, and quality assurance of the 
EHR4CR platform within hospitals, the project developed robust governance through 
accreditation and certification programmes for establishing best practices [21]. 
Considering that the EHR4CR platform has considerably evolved since its inception, and 
given its conclusive pilot testing, it has now reached the commercialization phase and is 
being scaled up across Europe. Since EHR4CR solutions have been designed to enhance 
and speed up current practices, it is predicted that they will transform clinical research 
environments, and generate substantial benefits for all stakeholders involved [2, 22]. 
Consequently, building a business ecosystem and creating sustainable business models 
are essential in order to successfully implement new technologies in healthcare, and to 
maximise the value that they can bring to health systems, healthcare organisations, care 
professionals, patients, care givers, citizens, and to society [23-27]. 
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The main objective of our study was to design a comprehensive multi-stakeholder 
business ecosystem and to assess the financial sustainability of exploiting the EHR4CR 
platform from the perspective of an EHR4CR service provider. This paper describes the 
methodology used to ensure that EHR4CR solutions are deployed and exploited in a 
sustainable manner in Europe, and beyond.  
2. Materials and methods 
2.1 Market analyses 
At the start of the project, a multidisciplinary Business Modelling Innovation Task Force 
(BMI-TF) was established to guide the design of a business model for the deployment 
and sustainable exploitation of the EHR4CR platform. The BMI-TF consisted of up to 15 
senior representatives from EHR4CR consortium partners who were invited to participate 
based on their expertise and interest in business modelling (i.e. academic experts, 
specialists in EHR research and quality labelling, senior clinical research scientists from 
6 participating pharmaceutical companies, clinical research organisations, representatives 
of patient organisations), including business modelling and health economics experts 
(designated sub-contractors to the project).  Over the duration of the project, the BMI-TF 
met every quarter for a total 12 multidisciplinary workshops. The purpose of these 
workshops was to co-develop the EHR4CR ecosystem and to design and align the 
components of a sustainable business model (i.e. definition of the strategic plan, vision, 
mission and core values, multi-stakeholder value chain, value propositions adapted by 
stakeholder group, sustainability strategies, business model framework, and market 
assumptions for conducting advanced business model simulations). Before each BMI-TF 
workshop, an agenda and reading material were prepared and disseminated to the 
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participants in order to optimise the outcomes. During the multidisciplinary workshops, 
strategic input was gathered through plenary and breakout sessions using small group 
discussions and interactive posters. After each workshop, the discussions were 
synthesised, and again disseminated to the BMI-TF members for further input until the 
next quarterly workshop. An evaluation of each workshop was conducted so to monitor 
progress and ensure continuing improvement. In order to gather additional market 
insights from the primary sponsors of clinical trials, the BMI-TF also organised a total of 
3 annual strategic forums with senior clinical research pharma executives who were 
personally invited by each participating EHR4CR pharmaceutical partner involved in the 
BMI-TF. The objectives of the strategic forums were to build engagement with the 
executive levels of participating pharmaceutical companies (as primary sponsors of 
clinical trials),  discuss the EHR4CR business modelling approach (including success 
factors and potential hurdles), and mitigate risks. Again, a detailed agenda and reading 
material were developed and disseminated ahead of each strategic forum. The insights 
gathered at each forum were synthesised in the format of executive summaries. An 
evaluation of each forum was also conducted with the participants.  
Over the duration of the project, members of the BMI-TF reviewed the literature relevant 
to market analyses. They conducted semi-structured interviews with clinical research 
experts from the academic and health policy sectors in order to identify emerging trends, 
opportunities and hurdles, and to stay abreast of new developments in a rapidly changing 
market landscape. The strengths, weaknesses, opportunities and threats (SWOT analysis) 
relevant to the EHR4CR platform and solutions were identified and analysed in relation 
with the political, economic, societal, technological and legal aspects (PESTL analysis). 
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These analyses were discussed at the BMI-TF workshops and during the strategic forums 
for defining the EHR4CR market landscape and business ecosystem. 
In order to define the clinical research environment, the BMI-TF conducted a pan-
European multi-stakeholder e-survey at project inception [2]. The objectives of the e-
survey were to investigate the perceived unmet needs, and the potential opportunities and 
issues related to the development and implementation of technological solutions that can 
improve clinical research processes. The survey questionnaire included a description of 
the EHR4CR project, and comprised a total of 30 multiple-choice questions investigating 
the following themes: i) demographic information; ii) areas for improvement in clinical 
research today; iii) key opportunities; iv) key challenges; v) expected benefits from the 
EHR4CR platform and services.  The questionnaire included questions relevant to 
implementing EHR4CR solutions (e.g. gaps and areas that were perceived as needing 
improvement in clinical research, level of support for reusing EHR data for research, 
opportunities, level of interest and organisational readiness for implementing EHR4CR 
services, research domains of interest for EHR4CR solutions, perceived contributors of 
data, resources and services,  funders and partners to consider in order to achieve research 
and business potential, resource availability, hurdles, and benefits of interoperable 
solutions).   
The e-survey was conducted via an online self-administered questionnaire with European 
informed stakeholders from 23 European countries. The stakeholders consisted of 
EHR4CR partners as well as external stakeholders involved in clinical research or 
Information and Communication Technologies (ICT), from different relevant sectors of 
activity [e.g. academic centres, information technology, EHR and electronic data capture 
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(EDC) system vendors, contract research organisations (CROs), clinical research sites, 
patient advocacy, hospitals, health agencies, pharmaceutical industry, etc.]. The e-survey 
was conducted by email invitation in two successive waves, the first one from June-July 
2011 (with EHR4CR partners), and the second, from July-September 2011 (with external 
stakeholders). For this purpose, the e-survey was disseminated by consortium partners 
through their contact networks to stakeholders across Europe, with a request for these 
recipients to further invite other colleagues. Rather like the distribution of questionnaires 
through large mailing list databases, non-response due to a lack of interest or willingness 
or lack of time could not be distinguished. Overall, there were 203 respondents (78 
respondents involved in the EHR4CR project and 125 who were not). Most of the 
respondents were from the UK (n=39), Germany (n=36), Belgium (n=24), Sweden 
(n=21), Switzerland (n=14) and France (n=14), the rest distributed across the remaining 
Member States. Respondents to this survey included stakeholders from academic centres 
(n=42), pharmaceutical industry (n=67), IT providers and EHR and EDC system vendors 
(n=38), clinical research organisations and sites (n=28), patient advocacy groups (n=4), 
health agencies (n=4), and other relevant sectors (n=20). Most respondents had an 
experience of more than 15 years within their sector of activity, providing domain-
specific expertise and proficiency. In October 2011, the survey responses from each wave 
were analysed separately by a senior statistician from the Centre for Health Informatics & 
Multiprofessional Education (CHIME), University College London.  The analysis 
highlighted the main areas for improvement in clinical research today, key opportunities 
and challenges, and the expected benefits from EHR4CR services for all stakeholders. 
Using relevant statistical tests, the results from both waves [2] were also compared to 
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show potential differences. The e-survey findings (which were used to guide the strategic 
development of the business model framework and its core components) are summarised 
in the Results Section.  
2.2 Vision, mission and core values  
Using the results of the pan-European e-survey and market analyses, the BMI-TF 
developed a strategic plan using a systematic approach [28-30]. As a first step, the 
BMI-TF defined the EHR4CR vision, mission and core values. The vision statement is 
future-based and consists of the long term goal to be achieved. It is a declaration of an 
organisation’s objective which defines the desired future state in terms of its strategic 
direction [31-33]. Because the vision is the inspiration providing the strategic planning 
framework, it is formulated as an inspiring pledge of what an organisation wants to 
become. In order to achieve the vision, the mission statement describes the purpose of the 
organisation [31, 33, 34], while the core values represent the principles by which the 
mission is to be conducted. As values are often culture-specific, they also guide an 
organisation’s strategic priorities and decisions [33]. 
2.3 Business ecosystem  
For ensuring the deployment of the EHR4CR platform and solutions, the BMI-TF 
envisioned a free market environment involving multiple interdependent stakeholders 
contributing to creating, delivering and capturing value in a scalable and sustainable 
manner. In order to optimise stakeholders’ interests, a framework fostering 
interdependencies was defined [35], taking into account market dynamics, industry 
drivers, and sustainability strategies.  In order to provide governance and to act as a 
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catalyst of this new business ecosystem, the BMI-TF proposed the creation of an 
independent institute. The different components of the business ecosystem are described 
in the Results Section.   
2.4 Multi-stakeholder value chain 
The BMI-TF developed a multi-stakeholder value chain in order to leverage the 
interdependencies. For this purpose, the BMI-TF identified key stakeholder groups and 
segmented them into four categories: i) Providers ii) Funders iii) Users, and 
iv) Beneficiaries of EHR4CR solutions. This functional categorisation contributed to 
structuring the environment for optimising value. The EHR4CR value chain is described 
in the Results Section.  
2.5 Customised value propositions 
Because they describe the benefits that new products or services provide to customers 
and stakeholders, value propositions are central to business models. The BMI-TF 
developed value propositions and adapted them in relation to the unmet needs identified 
by the market analyses. These descriptive value propositions are presented in the Results 
Section. Where relevant, the value propositions were substantiated with quantitative 
assessments using relevant stakeholders’ perspectives. 
2.6 Business model and implementation roadmap 
By definition, a business model describes the organisational framework and the processes 
involved in optimising the value that can be created, delivered and captured from 
leveraging innovative products, technologies and services [20]. Using the perspective of 
the EHR4CR service provider, the BMI-TF developed a business model canvas [20] by 
13	
	
populating nine building blocks: the customer segments of the EHR4CR service 
providers, the type of customer relationships and channels to be developed, the activities, 
resources and partnerships to be implemented and deployed, and the cost structure and 
revenue streams that will enable delivering the value propositions to the customer 
segments, in a sustainable manner. The financial scheme was established considering an 
EHR4CR service provider’s estimated expenses and revenue streams. The expenses were 
estimated in relation to the scope of activities to be implemented ( i.e. operational costs, 
salaries, overhead, commercial operations, data access fees, domain-specific experts, 
etc.), as well as  the revenue streams  (i.e. annual subscriptions for connecting clinical 
trials sponsors to the EHR4CR platform, fees per EHR4CR service, and potential 
licensing and consultative fees). These aspects were defined, discussed and populated by 
the BMI-TF considering the scope of the EHR4CR ecosystem, the multi-stakeholder 
value chain, the market analyses, the business intelligence gathered during the strategic 
forums, and the perceived success factors. An implementation roadmap was also 
developed to leverage the sustainability strategies that would optimise the delivery of the 
EHR4CR benefits to stakeholders. The components of the business model developed 
from the perspective of the EHR4CR service provider is summarised in the Results 
Section. 
2.7 Business model simulation 
The scope of the EHR4CR target market was defined considering the estimated number 
of commercially and non-commercially sponsored Phase II, III, IV clinical trials (CTs) to 
be conducted in Europe over 5 years by the following clinical trials sponsors’ segments: 
Pharmaceutical Research Organisations (PROs) and their CROs, as well as academic 
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Clinical Research Units (CRUs). Based on the European market landscape defined, the 
expected numbers of PROs, CROs and CRUs were estimated. All estimates are provided 
in the Results Section. 
The BMI-TF considered that EHR4CR solutions would be implemented in up to 5-10% 
of Phase II, III, IV CTs to be conducted in Europe over 5 years, with increasing market 
uptakes for each EHR4CR scenario in a non-mutually exclusive fashion. In order to 
forecast the financial outcomes, the business model simulation used market assumptions 
validated by the BMI-TF, including the categories of expenses and revenues considered 
for an EHR4CR service provider. The EHR4CR service providers’ yearly expenses were 
estimated by defining the estimated operational costs (minimum and maximum value 
ranges over a 5-year horizon) for each of the cost categories defined.   
The potential annual revenues for an EHR4CR service provider were calculated 
considering all revenue streams, including the EHR4CR fees for service (i.e. for 
enhancing and speeding up protocol assessment, patient identification for recruitment, 
and clinical data exchange including SAE reporting). Given the pre-launch context, 
EHR4CR fees for service were estimated as willingness-to-pay (WTP) ranges defined by 
6 participating EFPIA partners (2012) for each EHR4CR scenario, based on their 
business intelligence and perceived benefits of the EHR4CR platform. Those WTP 
assumptions were defined as small increasing percentage ranges of the average clinical 
trial per-patient costs across therapeutic areas, also considering the average estimated 
number of patients per CT. The revenues per service provider were then estimated 
considering the projected minimum and maximum number of Phase II, III, IV CTs for 
each EHR4CR service based on the potential market uptake of EHR4CR solutions in 
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Europe. Then, the profitability ratio (estimated revenues divided by the estimated 
expenses) was derived using simulation modelling.  
In order to manage uncertainty, probabilistic sensitivity analyses (10,000 Monte Carlo 
simulations[36]) were conducted taking into account data variance across the distribution 
of all parameters (i.e. between the minimum and maximum values provided) for the 
expenses and revenues estimated per EHR4CR service provider. 
3. Results 
3.1 Market analyses 
The e-survey results confirmed the gaps and areas for improving today’s clinical research 
processes, as well as the benefits and research opportunities that could be realised with 
the EHR4CR platform [2]. The clinical research processes identified as needing most 
improvement included: patient identification for recruitment in clinical trials (70% of 
respondents), time needed to conduct clinical trials (59 %), clinical research high costs 
and workload (54 %), and protocol feasibility assessment (50 %). The results from both 
waves showed a high degree of consistency across most aspects surveyed.  In addition,  
the vast majority (74%) of respondents expressed  interest in a value-driven EHR4CR 
platform rather than in a cost-saving platform, meaning that they were interested in value-
added (i.e. providing tangible benefits) and cost-effective solutions[2].   
3.2 EHR4CR vision, mission and core values  
Considering that the EHR4CR IMI project had declared the ambition of developing and 
establishing a scalable pan-European technological platform and service framework to 
enable the trustworthy re-use of patient-level data from hospital EHRs for clinical 
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research, a strategic plan was developed by the BMI-TF, including the definition of the 
EHR4CR vision, mission and core values (Table 1).  
Table 1. EHR4CR Vision, Mission and Core Values 
Vision 
Statement 
§ To be the trusted gateway to eHealth information for research and knowledge 
discovery to transform healthcare worldwide. 
Mission 
Statement 
§ Delivering sustainable value-added solutions for the trustworthy re-use of 
eHealth data and information to improve global clinical research. 
Core  
Values 
§ Provide flexible, scalable and interoperable solutions  
§ Ensure full compliance with relevant ethical, legal, regulatory, and privacy 
protection standards and policies  
§ Deliver innovative, customer-focused and sustainable value-added services  
§ Optimise healthcare connectivity by enabling adoption, collaboration, 
accountability and transparency. 
 
In order to build awareness and stakeholder engagement, educational material was 
developed and dissemination strategies were deployed throughout the duration of the 
project.  
3.3 EHR4CR business ecosystem  
The EHR4CR business ecosystem is based on the organisational framework described in 
Fig. 1, and involves the following actors: i) Data Providers (DP), i.e. hospitals to 
contribute anonymised hospital-based EHR health data for research purposes ii)  Service 
Providers (SP) to enable and deliver EHR4CR services to iii) Service Users (SU) (e.g. 
pharmaceutical industry, CRUs, CROs, etc.) to implement EHR4CR solutions for 
enhancing and speeding up clinical research processes (i.e. protocol feasibility 
assessment, patient identification for recruitment, and clinical data exchange). In this 
context, EHR4CR service providers will be new service entities, or existing organisations 
interested in providing EHR-enabled solutions for clinical research (e.g. trusted-third 
parties, CROs, and other vendors of the defined ecosystem). The business model assumes 
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that new business opportunities and potential alliances will emerge from this open market 
in which commercial interests will be stimulated, and where cooperation and competition 
(“coopetition”) will coexist.  As stated above, the EHR4CR solutions are now being 
commercialised and will be provided initially through InSite®, the first EHR4CR service 
platform (https://www.insiteplatform.com). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1  EHR4CR Scalable Business Ecosystem  
As described above and illustrated in Fig.1, the ecosystem involves the “European 
Institute for Innovation through Health Data (“i˷HD”)[37] (http://www.i-hd.eu/), a 
nonprofit independent organisation created to stimulate R&D opportunities, to provide 
governance for the research uses of health data, and to oversee accreditation and 
certification services for ensuring highest quality standards (i.e. data quality, 
interoperability, data privacy, ethics, etc.). Considering the scalable deployment of the 
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service platform, further stakeholders (e.g. network providers) are expected to join this 
dynamic ecosystem in the future, in order to expand its scope, including at the global 
level. 
3.4 EHR4CR multi-stakeholder value chain 
The market analyses conducted have emphasised the importance of developing a business 
model that addresses multi-stakeholders’ mutual interests. Contrary to a one-sided market 
(where suppliers and customers are independent from each other), multi-sided markets 
link two or more distinct but interdependent groups of stakeholders. These are 
proliferating today as modern information technology creates more opportunities for 
organising complex markets and business platforms [38, 39]. As business models are 
constructed by integrating interaction patterns and value chains [40],  the value chain 
developed by the BMI-TF and described in Fig. 2 illustrates that the EHR4CR ecosystem 
consists of a market where distinct groups of stakeholders provide each other with 
“network” (value chain) benefits (i.e. SP, DP, clinical trial sponsors, and citizens). In a 
traditional value chain, value moves from left to right. To the left of the organisation is 
cost; to the right is revenue. In multi-sided networks, cost and revenue are both to the left 
and the right[41]. As illustrated in Fig. 2, the value chain shows the interdependencies 
amongst stakeholders that contribute to creating, delivering, and optimising value across 
the EHR4CR network defined.		
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Fig. 2  Optimising the EHR4CR Multi-Stakeholder Value Chain 
 
 
3.5 EHR4CR customised value propositions 
The EHR4CR value propositions developed to reflect the unmet needs of different 
stakeholder segments are summarised in Table 2. These value propositions proved 
important during the development and refinement of the EHR4CR technical approach 
and business model as they helped to confirm the expected benefits, and the success 
factors that would be needed by each stakeholder to realise them.  
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Table 2: EHR4CR value propositions adapted by stakeholder group 
Stakeholder Segment Expected Benefits 
Service Providers § Enable seamless technological solutions for the research use of 
EHR-health data 
§ Build and grow a profitable and sustainable business landscape  
§ Leverage new business opportunities 
Clinical Trial Sponsors 
(pharmaceutical 
industry, CROs, CRUs) 
§ Enhance the efficiency of clinical trial processes 
§ Reduce the time and costs of bringing new drugs to market 
§ Generate added value 
Hospitals, Clinical 
Research Centers, 
Clinical Investigators 
§ Participate in more clinical research programmes 
§ Improve health data quality 
§ Enhance health care pathways 
§ Increase research activities and revenues 
ICT Industry 
(EHR/EDC vendors) 
§ Provide EHR solutions that will support  interoperable clinical 
data capture and exchange 
§ Develop business channels 
§ Grow existing market  
Patients § Benefit from more patient-centered clinical trials  
§ Gain access to safe and effective medicines, towards improving 
health outcomes and safeguarding patient safety 
Regulatory Bodies, 
Health Technology 
Assessors 
§ Generate high quality clinical efficacy, safety, cost-
effectiveness and comparative effectiveness evidence  
§ Support decision-making (marketing authorisation, 
reimbursement recommendations) 
Health Authorities, 
Health Care Planners, 
Governments 
§ Enhance health policies, public health programmes and 
decisions for optimising health care delivery and patient 
outcomes 
European Clinical 
Research Market 
§ Attract more R&D investments in Europe 
 
 
3.6 EHR4CR business model and implementation roadmap 
Using best practices [20], the business model summarised in the Appendix  was 
developed using the perspective of the EHR4CR service provider to establish an 
organisational business environment for enabling the deployment and sustainable 
exploitation of EHR4CR services. The EHR4CR business model highlights which 
customer segments the EHR4CR service providers should focus on, how they will be 
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reached, through which channels, for providing which services, and how this will be 
accomplished by leveraging key activities, resources and partnerships, and under which 
financial scheme. In order to optimise the adoption of new technologies and commercial 
success, the development of an adoption roadmap contributes to:  i) Planning the 
platform; ii) Establishing strategic partnerships; iii) Engaging the community for 
achieving full business potential. 
3.7 Business model simulation 
In order to assess the economic sustainability of the business model, the number of 
commercially sponsored and non-commercially sponsored Phase II, III and IV CTs to be 
conducted in Europe over the next 5 years was calculated. Multiple data sources were 
investigated. At the time of model development, the BMI-TF selected the EMA EudraCT 
2012[42] and its retrospective dataset (2007-2011) as baseline values. The worldwide 
average per-patient costs (USD) per Phase II, III and IV CTs across therapeutic areas 
under current practices were used as proxy (Table 3).  
Table 3: Estimated yearly number of commercially and non-commercially sponsored Phase II, 
III, IV CTs in Europe, and estimated average worldwide per-patient costs (USD) across 
therapeutic areas 
 
Clinical Trial 
(CT) Phase 
Number of CTs in 
Europe§ (2012) 
Retrospective Annual 
Ranges                   
(2007-2011) 
Average worldwide per-
patient costs (USD) per 
clinical trial phase across 
therapeutic areas† 
II 1,263 1,173-1,498 36,070 
III 926 817-1,148 47,609 
IV 729 637-908 17,042 
Source: §EudraCT 2012 (baseline), including commercially sponsored (PRO/CRO) and non-commercially sponsored clinical trials 
(CTs) (universities, hospitals, public organisations)  
†: Cutting Edge Report 2011 
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The estimated per-patient costs were obtained from the Cutting Edge database 
(http://www.cuttingedgeinfo.com) based on queries generated during the first quarter of 
2013.These estimated costs include: patient recruitment, vendor fees, technology, site 
retention, data cleaning, stats analysis, reports, patient retention costs. As the average 
worldwide per-patient costs vary across therapeutic areas (oncology being reported as the 
most costly) and geographic boundaries, and considering volatile exchange rates over the 
duration of the project, our baseline assumptions used a conservative average per-patient 
cost of 10,000 euros, and an estimated average of 250-500 patients/CT for the purpose of 
the business model simulation. In order to estimate the potential fees for service, our 
model then applied different ranges of increasing percentages to the per-patient costs 
baseline estimate, multiplied by the estimated average range of patients per CT. The 
business model simulation then calculated the profitability ratio taking into account 
potential variations by calculating the distribution of all potential values, across all the 
ranges provided, for all the parameters used to populate the model. 
In order to forecast the number of CTs that would be conducted in the next 5 years, the 
BMI-TF conducted a confidential survey with 6 pharmaceutical companies involved in 
the EHR4CR project. Their individual estimated annual projections were expressed as 
expected percentages of increase, decrease or no significant change in the number of 
Phase II, III and IV CTs to be conducted in Europe in the next 5 years (2014-2018). 
These percentages were defined as minimum and maximum values which were then 
computed and applied to the yearly estimated number of 2012 CTs in order to derive 5-
year cumulative forecasted ranges (Table 4).  
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Table 4: Estimated ranges of commercially and non-commercially sponsored Phase II, III, IV 
CTs in Europe  
Type Estimated annual number of  
Phase II, III, IV CTs                                 
(estimated ranges)§ 
Estimated 5-Year 
Cumulative Forecast 
(estimated ranges)† 
Commercial 1,000-1,500 4,900-9,285 
Non-commercial 1,580-1,680 7,740-10,395 
Total 2,580-3,180 12,640-19,680 
Source: §EudraCT 2012 (based on estimated baseline)  
†Ranges derived using pharmaceutical industry 5-year projections (2014-2018); Clinical Trials (CT) 
The EudraCT 2014 database statistics were later compared with the projected values, 
confirming the accuracy of the BMI-TF estimations. For the purpose of this study, the 
BMI-TF defined Phase IV CTs as well-controlled post-registration clinical trials, 
targeting special populations, or comparing a new intervention with current treatments 
(standard of care). Hence, Phase IV CTs excluded non-interventional observational 
studies for assessing comparative effectiveness in real-word contexts. Given an 
increasing demand for real-world evidence, it is however expected that studies conducted 
in real-world contexts would also benefit from the EHR4CR platform in the future.  
As indicated in Table 5, the BMI-TF estimated that a total of 5-15 EHR4CR service 
providers could collectively achieve up to 5-10% of market shares of Phase II,III,IV CTs 
to be conducted in Europe over 5 years. The potential 5-year market size (number of 
potential CTs) per EHR4CR service provider was estimated by applying the EHR4CR 
market shares on the estimated number of Phase II, III, IV CTs  that could use EHR4CR 
services, divided by the estimated number of accredited service providers.  
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Table 5: EHR4CR Business Model Assumptions 
Assumption Estimated Cumulative 5-year Ranges§ 
Estimated number of EHR4CR           
Service Providers 
 
5-15 
EHR4CR estimated 5-year                      
total CT market shares 
 
5-10% 
Estimated number of Phase II, III, IV CTs 
for EHR4CR solutions 
 
632-1,968† 
Total 5-year (min. and max.) estimated 
number of   Phase II, III, IV CTs per 
EHR4CR Service Provider  
 
42-394 
§Ranges established by the BMI-TF   Derived from applying 5-10% to the estimated 5-year forecasted ranges (Table 4)  
Clinical Trials (CT) 
 
The expenses and revenues estimated for an EHR4CR service provider were calculated 
for each category based on the assumptions defined by the BMI-TF. Considering a 5-year 
horizon, Table 6 summarises the underlying assumptions and the potential expenses and 
revenues (5 years annualised).  
25	
	
Table 6: Estimated expenses and revenues annualised per EHR4CR service provider 
Categories of 
Expenses 
Assumptions§ 
Potential Expenses 
Annualised§  
Min-Max (K€) 
Revenue Streams                
Assumptions§ 
Potential Revenues 
Annualised§  
Min-Max (K€) 
Human Resources 
(salaries, benefits etc.) 
1,130-2,225 Connecting to the EHR4CR 
Platform  
§ Annual subscription fees per 
clinical trial (CT) sponsor 
306-1,670 
Outsourcing 300-400 EHR4CR Scenario 1:  
Protocol Feasibility Assessment 
§ EHR4CR potential fees§†       
(2-4% of per-patient cost/CT) 
= 50-200K per CT 
§ Estimated yearly market uptake 
(applied to the EHR4CR 
estimated 5-10% CT market 
share): 
o Year 1-2: 3-7%  
o Year 3-5: 7-20% 
50-4,320 
Telecommunications 
and Equipment 
35-60 EHR4CR Scenario 2:  
Patient Identification for 
Recruitment 
§ EHR4CR potential fees§†         
(3-5% of per-patient cost/CT) 
= 75-250K per CT  
§ Estimated yearly market uptake 
(applied to the EHR4CR 
estimated 5-10% CT market 
share): 
o Year 1-2: 15-30%  
o Year 3-5: 30-60% 
270-17,740 
IT Infrastructure 35-60 EHR4CR Scenario 3:  
Clinical Data Exchange and SAE 
Reporting 
§ EHR4CR potential fees§†            
(5-10% of per-patient cost/CT) 
= 125-500K per CT  
§ Estimated yearly market uptake 
(applied to the EHR4CR 
estimated 5-10% CT market 
share): 
o Year 1-2: 1-5%   
o Year 3-5: 5-30% 
82.5-14,490 
Marketing 150 
Operating Fees 
(connecting data 
providers, data access 
fees, certification, 
accreditation, privacy 
protection, etc). 
308-10,268 
Overhead 190-200 
Office Supplies 20-30 
Juridical, Contractual, 
Insurance 
135-270 
Licensing fees 
(terminology, 
codes,etc.) 
75-150 
Travel Expenses  100-150 
§: Source: EHR4CR EFPIA partners 2012 
†: Expressed as willingness to pay ranges 
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As reported in Table 6, the EHR4CR estimated fees for services were derived for each 
EHR4CR scenario using the approach described in the Methods and materials section 
[i.e. by applying the WTP assumptions defined by EFPIA partners as marginal increasing 
percentage ranges of the average worldwide per-patient costs per CT across therapeutic 
areas (estimated at 10,000 euros/patient), multiplied by the estimated average range of 
patients per CT (250-500), yielding potential EHR4CR fees of 50-200K €/CT for 
Scenario 1; 75-250K €/CT for Scenario 2; and 125-500K €/CT for Scenario 3]. The 
potential revenues per service provider were derived considering the projected minimum 
and maximum number of CTs for each EHR4CR scenario.  The potential number of 
Phase II, III, IV CTs for each EHR4CR service was derived by applying increasing 
market uptake assumptions to the EHR4CR scalable 5-year CT market shares (5-10%).  
Using simulation modelling, the potential financial outcomes were estimated per service 
provider for exploiting the EHR4CR platform. The business simulation calculated the 
potential revenues assuming that the market uptake objectives set for each EHR4CR 
scenario would be achieved (Table 6). The potential revenues for exploiting the 
EHR4CR platform were estimated allowing service bundles between EHR4CR scenarios 
within the ranges of the market uptake objectives set for each, so that EHR4CR scenarios 
could potentially be used individually, in combination, or sequentially for a given CT 
(non-mutually exclusive). All potential values were screened by carrying out probabilistic 
sensitivity analyses according to specific distribution shapes. Using a random number 
generator programmed in D-Script language, 10'000 Monte Carlo simulations were 
performed on uniform or normal distribution shapes, depending on the type of data 
collected. The results were generated with their distribution parameters, as reported in 
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Table 7 (simulation summary of estimated expenses and potential revenues per service 
provider at Year 1), and as illustrated in Fig. 3 and Fig 4 (cumulative distribution 
curves). 
Table 7. Distribution parameters of estimated expenses and revenues per service provider -Year 1 
 
Measure Estimated expenses 
(Year 1) 
Estimated revenues 
(Year 1) 
Observations 10’000 10’000 
Mean 5018592.77 8917810.45 
Standard Deviation 2858952.59 3035781.48 
Variance 8173609891584.24 9215969197008.34 
Minimum 103927.82 1372410.36 
5th Percentile 604523.74 4000195.83 
Median 5002881.38 8925860.44 
95th Percentile 9514040.69 13791553.44 
Maximum 10002821.09 16418109.81 
 
 
 
 
 
 
 
Fig.3 Cumulative distribution of estimated expenses per service provider – Year 1 
 
 
 
 
 
 
 
 
 
 
Fig.4 Cumulative distribution of estimated revenues per service provider – Year 1 
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Assuming that the EHR4CR platform is fully operational and optimally deployed at time 
of launch, the results generated by the probabilistic sensitivity analyses suggest that an 
average profitability ratio (potential revenues divided by the estimated expenses) of up to 
1.8 could be achieved as of Year 1, with a growth potential in the subsequent years being 
dependent on the EHR4CR projected market shares. This theoretical simulation suggests 
that the EHR4CR business model appears profitable and sustainable, assuming that the 
EHR4CR platform would be commercially available at the beginning of Year 1 (i.e. post 
project), and that EHR4CR solutions would be quickly adopted by clinical research 
sponsors at project completion, followed by a swift and scalable EHR4CR market 
penetration across Europe in the subsequent years. This business model simulation is 
based on the market assumptions validated by the BMI-TF experts at the time of model 
development, and on the probabilistic sensitivity analyses across all the distribution 
ranges provided for all parameters.  
4. Discussion 
The widespread adoption of EHRs is accelerating through the richer collection of clinical 
data[43]. In addition, experts agree that EHRs can help achieve integrated health care, 
optimise health outcomes, reduce errors, curb costs and improve quality of care [44, 45]. 
As patient care moves from in-patient to ambulatory or other fragmented models of 
service delivery using multiple healthcare providers, the portability, interoperability and 
timely access to data have become increasingly important[44, 46]. It is expected that the 
increasing exploitation of EHRs will facilitate population-based health care models and 
outcomes research[45]. Data mining research is also growing in the world of data 
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integration, health information exchange, decision support systems, and knowledge 
discovery, and huge investments are being made in this research sector [44, 46].  
However, considerable hurdles must be overcome [47], including privacy and security 
issues[48], and other practical, technological, economic, political, professional and 
societal barriers which impede the exploitation of EHR [45, 47]. In particular, patients 
expect safe and high-quality care, privacy protection, rights of access and correction, and 
the opportunity to give consent for research uses of their health information [45, 48]. 
Nonetheless, the vast deployment of EHRs in Europe and the development EHR4CR 
innovative platform are providing a ground-breaking opportunity to pioneer the research 
use of EHR health data[22]. As the pharmaceutical industry is remodelling its R&D 
platforms to enhance its value chain, reduce costs and improve efficiency [3, 49-53], 
EHR4CR solutions promise to transform the clinical research landscape by enhancing 
and speeding up existing clinical research processes. Using a scalable approach, the 
deployment of EHR-enabled solutions for research will  generate new business 
opportunities with significant growth potential for all stakeholders involved,  as well as 
added value for clinical trial sponsors [52, 53], for the benefit of patients, health systems, 
and society[2]. 
4.1 Creating value 
While public funding is helpful in the development stages, there is a high demand for 
flexible and service-oriented business models [5, 9, 44]. In order to guide the sustainable 
exploitation of EHR4CR solutions by accredited service providers, a comprehensive 
business model was developed by the BMI-TF. As described in the Appendix, the 
business model proposes that EHR4CR service providers implement specific activities to 
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create value. Such activities include developing and maintaining the EHR4CR platform, 
building the connecting capacity, delivering trustworthy EHR4CR solutions in 
compliance with data protection and privacy requirements, establishing and growing the 
customer base, expanding the reach and scope of services over time (including globally), 
building stakeholder engagement, leveraging research opportunities, and generating 
evidence-based value assessments. The main resources to be deployed will include IT 
experts, sales and marketing resources, management and administrative support, and 
domain-specific experts. Moreover, partnerships will be established with key 
stakeholders (e.g. the i˷HD, clinical trials’ sponsors, data providers, academic leaders, 
industry, specialised media, etc.) so to build further awareness and advocacy, accelerate 
the adoption of EHR4CR services, identify new business needs and channels, and 
develop new solutions. For instance, by promoting the research use of health data, 
guiding the cohesive development of research platforms, and delivering accreditation and 
certification programmes ensuring that highest quality requirements and standards are 
met [2, 21, 22],  the i˷HD will contribute to establishing best practices, building trust, and 
achieving a sustainable ecosystem driven by innovation and excellence across Europe, 
and beyond.  
4.2 Delivering value 
The primary customer segments for EHR4CR service providers were defined as clinical 
trial sponsors (pharmaceutical industry and their designated CROs), and CRUs (academic 
clinical research centers). In this emerging market, trusted and long-term relationships 
will be developed by delivering reliable services and meaningful value propositions, 
building a well-connected EHR4CR community (i.e. a European network of excellence), 
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and establishing best practices for the research use of health data. Customer channels will 
include direct service offerings to the primary customer segments, and indirect reach by 
engaging and leveraging data providers (hospitals) and EHR/EDC industry networks. 
Value propositions were thus tailored to address the specific unmet needs of key 
stakeholders, and where relevant, substantiated with quantitative assessments.  In 
particular, a cost-benefit assessment [52, 53] and a budget impact analysis[54] were 
carried out from the perspective of primary sponsors of clinical trials, establishing the 
added value and the financial impact of using EHR4CR solutions compared to current 
practices. While these assessments were highly conclusive, they are based on validated 
assumptions, including market readiness in Europe and a swift adoption of EHR4CR 
solutions at project completion. This evidence of value will continue to be generated 
(including in real-world conditions) and disseminated broadly in order to build further 
awareness and strong multi-stakeholder engagement across Europe. 
4.3 Capturing value 
The business model simulation was carried out from the perspective of an EHR4CR 
service provider, confirming that the exploitation of the EHR4CR platform represents a 
commercial opportunity for opening new business channels, diversifying an existing 
business portfolio, building organisational expertise, and capturing business value. As 
described in the Results Section, the estimated financial outcome is reported for any 
given EHR4CR service provider, assuming similar operational conditions for all. 
In order to optimise value and achieve sustainability, EHR4CR service providers will 
need to develop their respective business plans, as well as the full scope of activities and 
resources to be deployed in the first year(s) of operation, including their competitive 
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service offering, cost structure, revenue streams, pricing schemes, and commercial 
performance metrics. Moreover, the proposed business model should ideally be managed 
and revisited periodically in response to evolving markets’ needs, emerging business 
intelligence, competitive activity, etc. This would contribute to engaging the EHR4CR 
community in establishing best practices in business model innovation and value 
optimisation.  
For achieving its full business potential, the EHR4CR plaform will also have to overcome 
several threats such as often inadequate and inconsistent clinical documentation within 
EHR[21]. This will require building awareness and clearly describing to the medical 
comunity, data providers, EHR/EDC vendors, patients, CROs, and clinical trials sponsors 
the benefits of enabling the use of EHR health data for research. This would ensure that 
optimal systems and processes are established in order to collectively improve the quality 
of health data for research. In some cases, this may require additional investments to 
upgrade existing IT infrastructures, source data systems, and data collection processes, as 
well as dedicated efforts for establishing best practices and optimising benefits for all 
stakeholders.  
In addition, the EHR4CR platform will require achieving optimal interoperability across 
EHR systems in order to offer a seamless and reliable end-to-end user experience. 
However, the near-universal downscaling of many national eHealth programmes might 
limit the investments in extending the richness and interoperability of EHR systems, and 
of the infrastructure to enable them to communicate at a regional or national level. This 
may have an impact on the costs and efforts required by EHR4CR service providers to 
link up individual hospitals to the platform, and on the estimated profitability ratio, 
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especially in the first years of operation. As a result, it may be necessary to prioritise an 
affordable first wave of services that limits such costs until the value proposition and 
business justification for enrichment are evident from early success.  
4.4 Study Limitations  
Regarding study limitations, this business model simulation remains a theoretical 
demonstration developed in the context of a European project, and does not necessarily 
reflect real-world commercial conditions. In addition, our model assumes that a 
commercial-grade version of the platform will be deployed and will be operational at the 
start of the 5-year period. While the simulation does take into account some maintenance 
functions, it currently does not include any further investments in R&D or commercial 
operations. For this reason, the uncertainty was managed using probabilistic sensitivity 
analyses so to appropriately reflect the full scope of the underlying assumptions.   
While our profitability analysis appears conclusive, it assumes that all market uptake 
objectives set for the EHR4CR scenarios would be achieved within the ranges and 
timelines forecasted. Although Year 1 profitability ratio may appear overly optimistic by 
assuming market readiness at the time of launch, this assumption considers that 
substantial efforts have been deployed throughout this 5-year project in order to build 
awareness, engage key stakeholders, and prepare the market. This suggests that the 
profitability forecast would likely be even more achievable for the second year, when the 
initial market has been established. Nonetheless, the business model simulation uses 
conservative market penetration estimates in order to reflect a progressive market uptake 
and a scalable deployment, as planned. Furthermore, simulation models being useful to 
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generate quantitative assessments, ours could be revisited in the future, and populated 
with data generated in real-world conditions (i.e. post-commercialisation).  
Importantly, the business model simulation having been conducted in a pre-launch 
context, it does not take into account specific pricing strategies and future commercial 
offers (e.g. competitive service bundling, discounts, etc.) that may be established by 
different EHR4CR service providers. Considering that a key feature of multi-sided 
markets is the innovative pricing strategies they employ (i.e. to attract one group of users, 
other group of users may be subsidised [55]), competitive pricing will also directly 
influence the EHR4CR market uptake and profitability margins. Again, it would be 
interesting to conduct subsequent economic analyses using real-world evidence (i.e. once 
the EHR4CR solutions are implemented). Such analyses would provide additional 
evidence to substantiate value propositions to clinical trial sponsors, data providers, and 
EHR industry. 
Despite these limits, and considering the inherent challenges related to the adoption of a 
new technology, this business model establishes that EHR4CR solutions will create, 
deliver and optimise value for all stakeholders involved. Because our profitability 
analysis is situated somewhat in the future, new or disruptive technologies could also 
influence the clinical research landscape and affect the conclusions of this study.  Until 
then, it will be important that the business model roadmap continues to build the demand 
for EHR4CR services, demonstrates its value (including in real-world contexts), and 
leverages stakeholder engagement and dissemination strategies, in Europe and beyond.  
 
 
35	
	
4.5  Outlook for the future 
Amongst other emerging technologies in the health sector, the EHR4CR platform will 
transform the clinical research landscape by enabling the re-use of hospital-based EHR 
patient-level data for research. This study has described the methods used for gathering 
and analysing multi-source business intelligence towards developing a sustainable 
business model for the EHR4CR platform, and for assessing its economic sustainability.  
In this emerging business ecosystem, EHR4CR service providers will be uniquely 
positioned to deliver trustworthy innovative and value-added solutions in compliance 
with all audit requirements and policies. Using a scalable approach, they will be 
empowered to rapidly grow this market and to establish trusted relationships with clinical 
trial sponsors, as well as best practices with the multi-stakeholder network of excellence 
enabled by the i˷HD. The adoption of a systematic business model innovation process 
will allow EHR4CR service providers to regularly update the proposed business model in 
response to market demands, and to generate added value in a consistent manner. By 
leveraging new research opportunities, including for generating evidence of value from 
real-world contexts, EHR4CR service providers will contribute to creating new business 
opportunities, and to building further sustainability. 
For clinical trial sponsors, the EHR4CR platform represents a breakthrough innovation to 
optimise R&D value chains, reduce operational costs, add substantial value, and enable 
the delivery of safe and effective innovative medicines to healthcare faster. For data 
providers, service providers and the ICT industry, the EHR4CR platform will establish 
new benchmarks and best practices in advancing today’s clinical research, and exploiting 
new business opportunities and revenue streams. For patients, health authorities, and 
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society, EHR4CR will provide revolutionary solutions that will contribute to optimising 
societal value and health outcomes, in Europe and worldwide.  
5. Conclusions 
The EHR4CR project has demonstrated that a detailed and robust business modelling 
methodology provides important insights on how the results of an R&D project should be 
sustained. The authors have learned that business modelling plays an important, but often 
undervalued, role in directing the strategic direction of a research endeavour, and should 
be undertaken in parallel to the research, not towards the end of the project. They believe 
that research leaders and research funders should more strongly promote the importance 
of business modelling as a key part of a research methodology and work plan. 
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Summary Table 
What was already known on the topic 
§ Clinical research faces major bottle necks as well as escalating costs 
§ Clinical trials design is often sub-optimal, leading to costly protocol amendments  
§ Patients’ enrolment in clinical trials is slow and time consuming, leading to important delays 
§ Study conduct is lengthy and laborious, and the reporting of serious side effects is poor 
§ EHR represent significant sources of health data for research purposes 
 
What this study added to our knowledge 
§ Sustainable business models are needed to optimise the value of new technologies 
§ A multi-stakeholder value chain contributes to maximising the benefits for all stakeholders 
§ Meaningful value propositions are key enablers for engaging stakeholders  
§ Robust business model simulations guide the successful deployment of new technologies 
§ Real-world value assessments are needed to enrich and strengthen initial value propositions 
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Appendix 
Online Appendix: Business model components using the perspective of EHR4CR service 
providers§ 
1. Primary 
Customers  
§ Clinical Trial Sponsors (pharma, CROs, academic clinical research units) 
2. Customer 
Relationships 
§ Establish a dynamic EHR4CR community and best practices 
§ Build and support a European network of Excellence 
§ Develop trusted and long term business relationships   
3. Customer 
Interface 
§ Direct reach and stakeholder engagement 
§ Indirect (leverage EHR/EDC and hospital network) 
4. Value 
Propositions 
§ Deliver trustworthy EHR4CR value-added services  and customised value 
propositions based on evidence of EHR4CR benefits, value creation and 
optimisation 
5. Main Activities § Develop and maintain an advanced technology platform 
§ Build and grow the customer base 
§ Deploy and expand services and reach  
§ Build stakeholder engagement and advocacy 
§ Leverage research opportunities 
§ Conduct evidence-based value assessment  
6. Main Resources § IT experts 
§ Sales & Marketing 
§ Management and Administrative Support 
§ Domain-Specific Experts 
7. Partnerships 
/Alliances 
§ European Institute for Innovation through Health Data (i˷HD) 
§ Pharmaceutical Industry Associations, CROs 
§ Hospitals and research centers 
§ EHR/EDC Vendors 
§ Academic leaders 
§ Media 
8. Expenses § Operational expenses  
§ Work contracted out (domain-specific experts) 
§ Licensing and data access fees 
9. Revenues § Annual subscriptions (connecting fees) 
§ EHR4CR fees for service  
§ Potential consulting fees (long term) 
§Adapted	from:	Osterwalder	A,	Pigneur	Y.		Business	Model	Generation.		2009[20]	. 
 
